These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36262171)

  • 1. Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.
    Kim D; Choi JO; Kim K; Kim SJ; Jeon ES
    Int J Heart Fail; 2020 Oct; 2(4):231-239. PubMed ID: 36262171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
    Warner AL
    Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
    Yamamoto H; Yokochi T
    ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
    Smiley DA; Rodriguez CM; Maurer MS
    Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
    Chatzantonis G; Bietenbeck M; Elsanhoury A; Tschöpe C; Pieske B; Tauscher G; Vietheer J; Shomanova Z; Mahrholdt H; Rolf A; Kelle S; Yilmaz A
    Clin Res Cardiol; 2021 Apr; 110(4):555-568. PubMed ID: 33170349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heart damage in the combined types of systemic amyloidosis].
    Rybakova MG; Vlasova MT; Kuznetsova IA; Krylova YS
    Arkh Patol; 2021; 83(5):21-26. PubMed ID: 34609800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the diagnosis and management of amyloid cardiomyopathy.
    Nijst P; Tang WW
    Fac Rev; 2021; 10():31. PubMed ID: 33817700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.
    Paeng JC; Choi JY
    Nucl Med Mol Imaging; 2021 Apr; 55(2):61-70. PubMed ID: 33968272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.
    Kaiser ME; Lewis TJ
    Cureus; 2023 Dec; 15(12):e50527. PubMed ID: 38098740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
    Debonnaire P; Claeys M; De Smet M; Trenson S; Lycke M; Demeester C; Van Droogenbroeck J; De Vriese AS; Verhoeven K; Vantomme N; Van Meirhaeghe J; Willandt B; Lambert M; de Paepe P; Delanote J; De Geeter F; Tavernier R
    Acta Cardiol; 2022 Nov; 77(9):791-804. PubMed ID: 34565298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid transthyretin cardiac amyloidosis: diagnosis and management.
    Di Giovanni B; Gustafson D; Delgado DH
    Expert Rev Cardiovasc Ther; 2019 Sep; 17(9):673-681. PubMed ID: 31478389
    [No Abstract]   [Full Text] [Related]  

  • 14. The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis.
    Kwok CS; Moody WE
    Ther Adv Cardiovasc Dis; 2023; 17():17539447231216318. PubMed ID: 38099406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EXPRESS: Epidemiology, Diagnosis and Management of Cardiac Amyloidosis.
    Bashir Z; Younus A; Dhillon S; Kasi A; Bukhari S
    J Investig Med; 2024 Jun; ():10815589241261279. PubMed ID: 38869161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.
    Papantoniou V; Valsamaki P; Kastritis S; Tsiouris S; Delichas Z; Papantoniou Y; Tsiouma M; Athanasoulis T; Fotopoulos A; Dimopoulos MA
    Hell J Nucl Med; 2015; 18 Suppl 1():42-50. PubMed ID: 26665211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy.
    Fontana M; Porcari A; Hawkins PN
    Glob Heart; 2023; 18(1):63. PubMed ID: 38028963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.
    Jung MH; Chang S; Han EJ; Youn JC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Treatment of Cardiac Amyloidosis.
    Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
    Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.